Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 36, 2868-2873, August 1, 1976]
© 1976 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Izzo, M. J.
Right arrow Articles by Bale, W. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Izzo, M. J.
Right arrow Articles by Bale, W. F.

Preferential Localization and Rate of Loss of Labeled Alloantibody from Rat Tumors and Skin Transplants Carrying the Corresponding Alloantigen1

Mary J. Izzo and William F. Bale

Department of Radiation Biology and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642

125I-Labeled rat histocompatibility antibody was prepared from sera of Buffalo rats immunized with a transplantable fibrosarcoma induced by methylcholanthrene in a Fischer 344 rat. After i.v. injection this antibody was shown to localize with high specificity in transplants of a second Fischer 344 tumor or Fischer 344 skin grafts onto immunosuppressed Buffalo rats. These represent conditions such that only tumor or skin grafts carry the corresponding antigen. In skin transplants localization at 24 hr corresponded to 80% and in tumor to 30% of the injected dose in tissue equal to 1% of the rat weight.

However, rapid loss of the 125I label from the target tissues indicated that degradation of antibody fixed to target cells was rapid and that the half-time of the intact antibody was less than 2 days.

1 This work was supported by USPHS Research Grant CA-16749 from the National Cancer Institute, and under contract with the United States Energy Research and Development Administration with the University of Rochester, and has been assigned Report No. UR-3490-882.

Received 2/ 3/76. Accepted 4/22/76.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1976 by the American Association for Cancer Research.